Apex Biotechnology Corp.

Total Valuation

Apex Biotechnology Corp. carries a market capitalization of 3.02B, placing it among publicly traded companies globally. Its enterprise value stands at 2.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Apex Biotechnology Corp. currently has 99.95M shares outstanding.

Valuation Ratios

Apex Biotechnology Corp. trades at a trailing price-to-earnings ratio of 18.65. The price-to-sales ratio is 1.56, and the price-to-book ratio stands at 2.43.

Enterprise Valuation

On an enterprise value basis, Apex Biotechnology Corp. trades at an EV/EBITDA multiple of 16.41 and an EV/FCF ratio of 13.96. The EV/Sales ratio of 1.31 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.41 provides insight into valuation relative to core operating earnings.

Financial Position

Apex Biotechnology Corp. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.96, indicating elevated leverage, while an interest coverage ratio of 45.76 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Apex Biotechnology Corp. posts a return on equity of 13.22 and a return on invested capital of 6.56.

Taxes

Over the trailing twelve months, Apex Biotechnology Corp. has paid 26.86M in income taxes, reflecting an effective tax rate of 14.14.

Stock Price Statistics

Apex Biotechnology Corp.'s stock has gained approximately 4.67128% over the past 52 weeks. The 50-day moving average sits at 29.25, while the 200-day moving average is 30.67.

Income Statement

Over the trailing twelve months, Apex Biotechnology Corp. generated 1.94B in revenue and converted that into 162.89M in net income, yielding earnings per share of 1.63. EBITDA reached 155.05M, while operating income came in at 155.05M.

Balance Sheet

Apex Biotechnology Corp. holds 644.37M in cash and equivalents against 148.86M in total debt, resulting in a net debt position of -527.90M. Total book value stands at 1.25B, with working capital of 1.24B providing operational flexibility.

Cash Flow

Apex Biotechnology Corp. produced 160.12M in operating cash flow over the past twelve months. After subtracting -19.26M in capital expenditures, free cash flow totaled 140.86M - equivalent to 1.41 per share.

Margins

Apex Biotechnology Corp. operates with a gross margin of 27.70, reflecting its pricing power and cost economics. The operating margin of 7.97 and net profit margin of 8.38 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Apex Biotechnology Corp.'s most recent stock split took place on July 1, 2009 with a 20:23 split ratio.

Scores

Apex Biotechnology Corp. posts an Altman Z-Score of 5.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.